[Form 4] IBEX Limited Insider Trading Activity

Rhea-AI Filing Summary

IBEX Ltd director and Chief People Officer Paul Joseph Inson reported a sale of 10,000 common shares on 08/22/2025. The shares were sold in multiple trades at prices ranging from $30.00 to $30.13, with a weighted average sale price reported as $30.0013. After the sale, the reporting person beneficially owned 7,352 shares directly. The filing also indicates the transaction was made pursuant to a prearranged plan intended to satisfy Rule 10b5-1(c), and the filer offers to provide trade-by-trade pricing details upon request.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating trades were prearranged and may reduce concerns about trading on material nonpublic information
• Filer disclosed price range ($30.00–$30.13) and offered to provide per-trade details, increasing transparency

Negative

• Insider sale of 10,000 shares reduced direct beneficial ownership to 7,352 shares, which could be viewed negatively by some investors absent further context

Insights

Securities Analyst

TL;DR: An officer sold a modest block of shares under a 10b5-1 plan; this is routine disclosure, not an immediate alarm.

The sale of 10,000 shares by the Chief People Officer at ~$30 per share reduced direct holdings to 7,352 shares. The filing checks the box indicating the use of a Rule 10b5-1 plan, which typically signals the trades were preplanned and may mitigate concerns about contemporaneous insider knowledge. The disclosure includes an offer to provide per-trade pricing details, enhancing transparency. Absent additional context on company size or percentage ownership change, this appears to be a standard insider disposition rather than a material corporate development.

Corporate Governance Expert

TL;DR: Proper Form 4 mechanics were followed; use of 10b5-1 and explicit pricing range improves compliance visibility.

The report identifies the reporting person, role, and address, and includes the required signed certification by an attorney-in-fact. Notably, the filer disclosed the trade price range and committed to provide per-trade details if requested, which supports governance best practices for transparency. The filing does not state whether the sale was motivated by personal diversification, tax planning, or other reasons, so governance implications are limited to procedural compliance rather than stewardship concerns.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Inson Paul Joseph

(Last) (First) (Middle)

C/O IBEX LIMITED

1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)

WASHINGTON DC 20006

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief People Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	08/22/2025		S		10,000	D	$30.0013(1)	7,352	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed in multiple trades at prices ranging from $30.00 to $30.13; the price reported above reflects the weighted average sales price. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

Remarks:

	Lisa Lenstrohm, Attorney-in-Fact	08/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the IBEX (IBEX) Form 4 filed by Paul Joseph Inson report?

The Form 4 reports a sale of 10,000 common shares on 08/22/2025 executed in multiple trades at prices between $30.00 and $30.13, leaving the reporting person with 7,352 shares.

Was the sale by the IBEX officer part of a 10b5-1 trading plan?

Yes. The filing indicates the transaction was made pursuant to a plan intended to satisfy Rule 10b5-1(c).

What price was reported for the shares sold in the IBEX Form 4?

The weighted average sale price reported is $30.0013, with individual trade prices ranging from $30.00 to $30.13.

How many shares does the reporting person own after the transaction?

7,352 common shares are reported as beneficially owned following the sale.

Who signed the Form 4 for the reporting person?

Lisa Lenstrohm, Attorney-in-Fact signed the Form 4 on behalf of the reporting person on 08/22/2025.